TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Summed difference in binodenoson and adenosine reader-generated Summed Difference Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Summed difference in adenosine- and adenosine-2 reader-generated Summed Difference Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extreme discrepancies in binodenoson and adenosine reader-generated Summed Difference Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extreme discrepancies in adenosine- and adenosine-2 reader-generated Summed Difference Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Toxicities Related to Infusion of Expanded Cord Blood Products
Endpoint domain: Adverse events/effects
Primary endpoint: Neutrophil Engraftment Within 21 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tmax & t1/2 Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-EPO-R antibodies staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of healthy volunteers enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in brain excitability measured through motor evoked potentials (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in baseline Multiple Hop Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline weight bearing lunge test (WBLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline Star Excursion Balance Test (SEBT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline Foot and Ankle Ability Measure (FAAM)- Activities of Daily Living (ADL) Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline Foot and Ankle Ability Measure (FAAM)- Sport subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of nasal carriage of Staphylococcus aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline in vital signs (blood pressure, pulse rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immunolocalization of PD-1, PD-L1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of upper extremity motor function using Fugl-Meyer scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of upper extremity performance using Action Research Arm Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Grip strength % using Dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Profile of Mood States response
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Digit Symbol Coding response
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Hopkins Verbal Learning Test response
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Splenic salvage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in mean cardiac index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the curve (AUC) of ODM-201
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ODM-201
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Sodium Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection rate of femoral neck fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Retinal venous pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Level of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Jumping in centimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Velocity in seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of direction in seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inter-limb asymmetry in %
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of acute postthoracotomy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of system reactions
Endpoint domain: Adverse events/effects
Primary endpoint: amount of alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to lapse
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Change from Baseline Balance Berg Scale (BBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Carotid Chemosensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the proportion of abnormal MRIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of treatment-related limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Pigmentation clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Perceived Stress Scale (PSS-10) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Protective efficacy to prevent acquisition of genital herpes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Dosimetry of F-18 THK-5351
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy for shortening duration of SAR-CoV2 detection by PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical treatment target motion and deformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance of any unexpected grade 3 or 4 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Invasive hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bacterial Colonization (Gram stain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants Who Developed Target Joint Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Perceived Stress Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Food Action and Acceptance and Action Questionnaire (FAAQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in muscle tissue oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Midazolam AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fexofenadine AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Month 6
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: log10 HIV RNA change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Renal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cerebral oxygenation (ScO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduced non-ventilator hospital acquired pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Renal arterial resistivity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in the Diffusing Capacity of the Lung for Carbon Monoxide (DLco)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in Oxygenation (PaO2/FiO2 Ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Effectiveness of sorafenib in TACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of subjects with effective exclusion of ASA
Endpoint domain: Adverse events/effects
Primary endpoint: Change of copeptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: number of cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression -- Improvement (CGI-I) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical Global Impression -- Severity (CGI-S) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Half life of CPGJ602 in blood [t1/2]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events [AEs]
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Seroprotected for HI Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Geometric Increase (MGI) for HI Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Obstructive Sleep Apnea severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Performance of the MassPLEX Factor II/V Leiden Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: new immunization doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Enrollment (14 Days)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of Logging in (14 Days)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Severity of ocular and cardiovascular PXE manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Extent of PXE skin changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in infant weight (z-score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of fistulas number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Grade 4 Hematology Toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients with treatment related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Indices of social attention deployment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indices of electrodermal activity (EDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total Mayo Score (tMS) at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants Who Demonstrated Clinical Remission by Adapted Mayo Score Components at Maintenance Week (mWeek) 44
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of bedwetting episodes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized AUC 0-24h of FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Trajectory of Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Trajectory of Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pruritus at outer ear canal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Psychological events
Endpoint domain: Adverse events/effects
Primary endpoint: VZV ELISPOT response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occlusion of treated vein post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change From Baseline in Ashworth Score Evaluating Spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Change From Baseline in Subject's Global Impression (SGI) of Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incremental Recovery Following a Single Intravenous Dose of 50 IU/kg rIX-FP or Previous FIX Product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (t1/2) Following a Single Intravenous Dose of 50 IU/kg rIX-FP or Previous FIX Product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Developing Inhibitors to Factor IX (FIX)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of PV patients with absence of phlebotomy and hematocrit below 45%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of ET patients with a platelet count ≤ 400 x 10x9/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean FPG, PPG and HbA1c of diabetic patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of diabetic patients having dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Response Rate (Complete and Partial Responses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Nasal Obstruction Symptom Evaluation (NOSE) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of pain on the Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Neoplastic Lesions Detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Intraepidermal Nerve Fiber Density (IENFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MSQOL-54
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Five time Sit to Stand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OM-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differentiation of Iron deficiency anemia and Beta thalassemia trait
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: fetal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: maternal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Cervical mucosal healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motricity index strength assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hypotension episodes requiring intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: acute muscle wasting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: preoperative sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Safety of FMT
Endpoint domain: Adverse events/effects
Primary endpoint: Engraftment of donor microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency and intensity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: height and weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg volume measured with ESD (ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg volume measured with WDV (ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg circumference measured with tape measure (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg circumference measured with ESD (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with abnormal physical examination/ abnormal vital signs/ abnormal laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital length-of-stay (LOS)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Morbidity of surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Atherosclerosis (cIMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Complications of the disease or treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Prostate-Specific Antigen (PSA) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the OAA/S score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response prediction based on PD-L1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antineoplastic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical and parasitological efficacy of artemether-lumefantrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of treatment-related clinical and paraclinical adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in pharmacokinetic profiles of artemether-lumefantrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failed scan rate
Endpoint domain: Adverse events/effects
Primary endpoint: Failed automated MRI-scan data-analysis rate
Endpoint domain: Adverse events/effects
Primary endpoint: Responder Rate Based on the Blinded Evaluator's Live Assessment of the Galderma Infraorbital Hollows Scale (GIHS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social and Work Impairments
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Diagnostic Quality of Telerobotic Ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of total culture positivity
Endpoint domain: Adverse events/effects
Primary endpoint: Bone density change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximal aerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Product Preference for Immediate Taste
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Donors From Whom a Sufficient Number of Cells for Transplantation Are Collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of Recipients Who Experience Grade 2-4 Acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Recipients Who Successfully Engraft by Day +21 After Transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean systolic-diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Uncorrected Distance Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Subjective Refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of 5-ASA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in the NAPSI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Drop in Left Ventricular Ejection Fraction (LVEF) Below 45 Percent (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Withdrawn From Study Because of LVEF Dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Annualized Rate of Severe Exacerbation Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in visual memory assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean value of morning PEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: numerical rating scale at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: numerical rating scale during movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary incontinence on cough stress test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of suspected drug allergies
Endpoint domain: Adverse events/effects